Efficacy and Safety of Less Frequent/Lower Intensity Dosing of Talquetamab in Patients with Relapsed/Refractory Multiple Myeloma: Results from the Phase 1/2 MonumenTAL-1 Study

被引：30

作者：

Chari, Ajai ^{[1
]}

Oriol, Albert ^{[2
,3
]}

Krishnan, Amrita ^{[4
]}

Martinez Chamorro, Maria Del Carmen ^{[5
]}

Costa, Luciano ^{[6
]}

Mateos, Maria Victoria ^{[7
]}

Minnema, Monique C. ^{[8
]}

Campagna, Michela ^{[9
]}

Masterson, Tara J. ^{[10
]}

Hilder, Brandi W. ^{[10
]}

Tolbert, Jaszianne ^{[11
]}

Renaud, Thomas ^{[11
]}

Smit, M. Damiette ^{[12
]}

Ramanjulu, Swarna ^{[10
]}

Otero, Paula Rodriguez ^{[13
]}

机构：

[1] Mt Sinai Sch Med, New York, NY USA

[2] Hosp Germans Trias i Pujol, Inst Catala Oncol, Barcelona, Spain

[3] Hosp Germans Trias i Pujol, Inst Josep Carreras, Barcelona, Spain

[4] City Hope Natl Med Ctr, Judy & Bernard Briskin Ctr Multiple Myeloma Res, Irvine, CA USA

[5] Univ Hosp Quironsalud, Pozuelo De Alarcon, Madrid, Spain

[6] Univ Alabama Birmingham, Vestavia, AL USA

[7] Univ Hosp Salamanca IBSAL CIC CIBERONC, Salamanca, Spain

[8] Univ Med Ctr Utrecht, Utrecht, Netherlands

[9] Janssen Res & Dev, Madrid, Spain

[10] Janssen Res & Dev, Spring House, PA USA

[11] Janssen Res & Dev, Raritan, NJ USA

[12] Janssen Biol BV, Leiden, Netherlands

[13] Clin Univ Navarra, Pamplona, Spain

来源：

关键词：

D O I：

10.1182/blood-2023-181228

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：4